Drug Profile
SOU 001
Alternative Names: AA 10020; DRP 001; Stress incontinence therapy - Arachnova/Sosei HeptaresLatest Information Update: 13 Dec 2018
Price :
$50
*
At a glance
- Originator Unknown
- Developer Arachnova
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Stress incontinence
Most Recent Events
- 03 Dec 2018 Heptares Therapeutics has merged with Sosei to form Sosei Heptares
- 15 May 2006 Discontinued - Phase-I for Stress incontinence in USA (PO)
- 15 May 2006 Discontinued - Phase-II for Stress incontinence in United Kingdom (PO)